-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Benitec Biopharma (NASDAQ:BNTC) Versus BridgeBio Pharma (NASDAQ:BBIO) Critical Analysis
Benitec Biopharma (NASDAQ:BNTC) Versus BridgeBio Pharma (NASDAQ:BBIO) Critical Analysis
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for BridgeBio Pharma and Benitec Biopharma, as provided by MarketBeat.com.
Get BridgeBio Pharma alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BridgeBio Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopharma | 0 | 0 | 2 | 0 | 3.00 |
BridgeBio Pharma currently has a consensus target price of $23.00, indicating a potential upside of 172.84%. Benitec Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,613.80%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than BridgeBio Pharma.
Earnings and Valuation
This table compares BridgeBio Pharma and Benitec Biopharma's revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BridgeBio Pharma | $69.72 million | 18.07 | -$562.54 million | ($3.36) | -2.51 |
| Benitec Biopharma | $70,000.00 | 93.30 | -$18.21 million | ($119.48) | 0.00 |
Benitec Biopharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BridgeBio Pharma and Benitec Biopharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BridgeBio Pharma | -553.52% | N/A | -67.43% |
| Benitec Biopharma | N/A | -203.69% | -151.61% |
Risk and Volatility
BridgeBio Pharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
Institutional and Insider Ownership
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 69.7% of Benitec Biopharma shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.6% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
BridgeBio Pharma beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
About BridgeBio Pharma
(Get Rating)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
About Benitec Biopharma
(Get Rating)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
桥生物医药(纳斯达克：BBIO-GET评级)和贝尼泰克生物医药(纳斯达克：BNTC-GET评级)都是小盘医疗公司，但哪一家更好？我们将根据这两家公司的机构所有权、估值、分析师建议、盈利能力、股息、收益和风险的实力进行比较。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and recommmendations for BridgeBio Pharma and Benitec Biopharma, as provided by MarketBeat.com.
这是由MarketBeat.com提供的BridgeBio Pharma和Benitec Biophma最近的评级和推荐细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BridgeBio Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopharma | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 布里奇比奥制药 | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopma | 0 | 0 | 2 | 0 | 3.00 |
BridgeBio Pharma currently has a consensus target price of $23.00, indicating a potential upside of 172.84%. Benitec Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,613.80%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than BridgeBio Pharma.
BridgeBio Pharma目前的共识目标价为2300美元，表明潜在上行空间为172.84%。Benitec Biophma的共识目标价为4.00美元，表明潜在涨幅为1,613.80%。鉴于Benitec Biophma更有可能上行，分析师显然认为Benitec Biophma比BridgeBio Pharma更有利。
Earnings and Valuation
收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BridgeBio Pharma | $69.72 million | 18.07 | -$562.54 million | ($3.36) | -2.51 |
| Benitec Biopharma | $70,000.00 | 93.30 | -$18.21 million | ($119.48) | 0.00 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 布里奇比奥制药 | 6972万美元 | 18.07 | -5.6254亿美元 | ($3.36) | -2.51 |
| Benitec Biopma | $70,000.00 | 93.30 | -1,821万元 | ($119.48) | 0.00 |
Benitec Biopharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Benitec Biophma的收入低于BridgeBio Pharma，但收益高于BridgeBio Pharma。BridgeBio Pharma的市盈率低于Benitec Biophma，表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
This table compares BridgeBio Pharma and Benitec Biopharma's net margins, return on equity and return on assets.
此表比较了BridgeBio Pharma和Benitec Biophma的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| BridgeBio Pharma | -553.52% | N/A | -67.43% |
| Benitec Biopharma | N/A | -203.69% | -151.61% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 布里奇比奥制药 | -553.52% | 不适用 | -67.43% |
| Benitec Biopma | 不适用 | -203.69% | -151.61% |
Risk and Volatility
风险和波动性
BridgeBio Pharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
BridgeBio Pharma的贝塔系数为0.62，这表明其股价的波动性比标准普尔500指数低38%。相比之下，Benitec Biophma的贝塔系数为1.22，这表明其股价的波动性比标准普尔500指数高22%。
Institutional and Insider Ownership
机构和内部人持股
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 69.7% of Benitec Biopharma shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.6% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BridgeBio Pharma 96.5%的股份由机构投资者持有。相比之下，Benitec Biophma 69.7%的股份由机构投资者持有。BridgeBio Pharma 29.6%的股份由公司内部人士持有。相比之下，Benitec Biophma 1.6%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一只股票有望实现长期增长。
Summary
摘要
BridgeBio Pharma beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
BridgeBio Pharma在两只股票比较的13个因素中有7个击败了Benitec Biophma。
About BridgeBio Pharma
关于BridgeBio Pharma
(Get Rating)
(获取评级)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
BridgeBio Pharma，Inc.致力于识别和推进治疗孟德尔疾病患者的变革性药物。该公司正在进行的开发项目包括从早期发现到后期开发的候选产品。该公司由Charles Homcy、Frank McCormick、Philip Reilly和Neil Kumar于2015年创立，总部位于加利福尼亚州帕洛阿尔托。
About Benitec Biopharma
关于Benitec Biophma
(Get Rating)
(获取评级)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biophma Inc.是一家处于发展阶段的生物技术公司，专注于新型基因药物的开发。该公司开发基于DNA指导的RNA干扰的疗法，用于治疗慢性和威胁生命的人类疾病。该公司正在开发BB-301，一种基于腺相关病毒的基因治疗剂，用于治疗眼咽肌营养不良症。该公司成立于1995年，总部设在加利福尼亚州海沃德。
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
获得BridgeBio Pharma Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收BridgeBio Pharma和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧